
Cytisinicline resulted in clinically robust and significant improvements in smoking cessation over 6 and 12 weeks of treatment compared with placebo, according to topline results from the ongoing phase 3 ORCA-2 trial.
The ORCA-2 trial was designed to evaluate efficacy and safety of 3 mg cytisinicline (Achieve Life Sciences) three times daily for 6 weeks or 12 weeks compared to placebo. The trial enrolled 810 adult smokers (mean age, 54 years) who were monitored for smoking abstinence for 24 weeks following randomization to cytisinicline or placebo. Participants also received behavioral support